TCGA-H7-7774-01A-21R-2081-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.550
- BILE_ACID_METABOLISM+0.400
- CHOLESTEROL_HOMEOSTASIS+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
- XENOBIOTIC_METABOLISM+0.390
- ESTROGEN_RESPONSE_EARLY+0.370
- INTERFERON_GAMMA_RESPONSE+0.370
- ESTROGEN_RESPONSE_LATE+0.360
- PROTEIN_SECRETION+0.360
- MTORC1_SIGNALING+0.350
Top 10 suppressed
- ANGIOGENESIS-0.550
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- E2F_TARGETS-0.410
- MYC_TARGETS_V2-0.380
- DNA_REPAIR-0.350
- G2M_CHECKPOINT-0.320
- MYC_TARGETS_V1-0.210
- TNFA_SIGNALING_VIA_NFKB-0.180
- WNT_BETA_CATENIN_SIGNALING-0.150
- MYOGENESIS-0.130
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-6955-01A-11R-2016-07 | — | — | 0.925 |
| 2 | TCGA-OR-A5LH-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.791 |
| 3 | TCGA-CQ-6223-01A-11R-1915-07 | — | — | 0.783 |
| 4 | SRR15069614 | — | — | 0.782 |
| 5 | BS_AG3D3435 | subependymal giant cell astrocytoma(SEGA) | — | 0.763 |
| 6 | SRR8613769 | — | F | 0.762 |
| 7 | BS_EHVYJAVA | pilocytic astrocytoma | — | 0.759 |
| 8 | BS_2EMW8ZG3 | low-grade glioma | — | 0.747 |
| 9 | X44dc4429.1bfa.4845.b2ed.028feafe7d4a | — | cohortA1 | 0.744 |
| 10 | BS_Y0PCBNJV | pilocytic astrocytoma | — | 0.730 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.550 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.400 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.400 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.390 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.390 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.370 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.370 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.360 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.360 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.330 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.330 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.260 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.260 | Remibrutinib | — uncovered |
| PEROXISOME | 0.260 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.250 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |